OncoMatch/Clinical Trials/NCT06992336
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Is NCT06992336 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Anlotinib , and Benmelstobart for breast cancer.
Treatment: Anlotinib , · Benmelstobart · Capecitabine — Early triple negative breast cancer patients who do not achieve pathologic complete response after neoadjuvant chemotherapy with or without immunotherapy have bad prognosis. ctDNA effectively identified patients with highest relapse risk. This trial aims to explore whether the combination of anlotinib, immunotherapy and capecitabine could improve the outcome of this subgroup of high relapse risk patients compared with investigator's choice of therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 ER ≤ 10% (≤ 10%)
ER ≤ 10%
Required: PR (PGR) PR ≤ 10% (≤ 10%)
PR ≤10%
Required: HER2 (ERBB2) HER2 0-1 (0-1)
HER 0-1
Required: HER2 (ERBB2) HER2 2+ and FISH negative (2+ and FISH negative)
HER2 2+ and FISH negative
Disease stage
Required: Stage II, III
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify